Fulgent Genetics Reports 60% Response Rate for FID-007 in Head and Neck Cancer Phase 2 Trial
核心洞察
Fulgent Genetics (搜索) announced interim Phase 2 results for FID-007 combined with cetuximab showing a 60% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma patients.
The combination therapy achieved a median progression-free survival of 7.2 months with a favorable safety profile in patients who had progressed after PD-1 (搜索)-based immunotherapy.
The study evaluated two dosing regimens with most treatment-related adverse events being grade 1-2, though one grade 5 pneumonia event occurred.
Fulgent Genetics (搜索) has reported promising interim Phase 2 results for its investigational drug FID-007 in combination with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company announced on May 21, 2026, that the combination achieved a 60% objective response rate and median progression-free survival of 7.2 months in this hard-to-treat patient population.
Clinical Trial Results
The interim Phase 2 data, current as of December 20, 2025, evaluated two dosing regimens of FID-007 plus cetuximab in patients whose disease had progressed after PD-1 (搜索)-based immunotherapy. The study demonstrated what the company characterized as a favorable safety profile compared with historical standards in this patient population.
Most treatment-related adverse events were grade 1-2, with limited grade 3-4 toxicities observed. However, the trial did record one grade 5 pneumonia event. While overall survival data remain immature, the early efficacy and tolerability signals suggest a potentially meaningful new treatment option in the HNSCC market.
Market Context and Significance
The results address a significant unmet medical need in head and neck cancer treatment, where current therapies deliver modest response rates and short progression-free survival in the recurrent or metastatic setting. The global HNSCC market represents a substantial opportunity for new therapeutic approaches, particularly for patients who have exhausted standard treatment options including PD-1 (搜索)-based immunotherapy.
ASCO Presentation and Company Pipeline
The full abstract on FID-007 will be presented at the ASCO 2026 Head and Neck Cancer Track session on June 1 in Chicago. The results underscore the potential of FID-007 to strengthen Fulgent's emerging oncology franchise as the company seeks to evolve from diagnostics into a fully integrated precision medicine player.
Fulgent Genetics (搜索) operates as a technology-based precision medicine company with an established laboratory services business and a therapeutic development arm focused on oncology. The company's drug development unit utilizes a nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetics of cancer drugs.
The promising Phase 2 results have drawn both investor and clinical attention to Fulgent's therapeutic pipeline, representing a potential milestone in the company's transition toward becoming a comprehensive oncology-focused organization.